|
Originally published In Press as doi:10.1074/jbc.M001518200 on May 12, 2000
J. Biol. Chem., Vol. 275, Issue 39, 30002-30008, September 29, 2000
Human Lactoferrin Binds and Removes the Hemoglobin Receptor
Protein of the Periodontopathogen Porphyromonas
gingivalis*
Yixin
Shi,
Wei
Kong, and
Koji
Nakayama
From the Department of Microbiology, Faculty of Dentistry, Kyushu
University, Fukuoka 812-8582, Japan
Received for publication, February 22, 2000, and in revised form, May 10, 2000
 |
ABSTRACT |
Porphyromonas gingivalis possesses a
hemoglobin receptor (HbR) protein on the cell surface as one of the
major components of the hemoglobin utilization system in this
periodontopathogenic bacterium. HbR is intragenically encoded by the
genes of an arginine-specific cysteine proteinase (rgpA),
lysine-specific cysteine proteinase (kgp), and a
hemagglutinin (hagA). Here, we have demonstrated that human
lactoferrin as well as hemoglobin have the abilities to bind purified
HbR and the cell surface of P. gingivalis through HbR. The
interaction of lactoferrin with HbR led to the release of HbR from the
cell surface of P. gingivalis. This lactoferrin-mediated HbR release was inhibited by the cysteine proteinase inhibitors effective to the cysteine proteinases of P. gingivalis. P. gingivalis could not utilize lactoferrin for its growth as an
iron source and, in contrast, lactoferrin inhibited the growth of the
bacterium in a rich medium containing hemoglobin as the sole iron
source. Lactoferricin B, a 25-amino acid-long peptide located at the
N-lobe of bovine lactoferrin, caused the same effects on
P. gingivalis cells as human lactoferrin, indicating that
the effects of lactoferrin might be attributable to the lactoferricin
region. These results suggest that lactoferrin has a bacteriostatic
action on P. gingivalis by binding HbR, removing it from
the cell surface, and consequently disrupting the iron uptake system
from hemoglobin.
 |
INTRODUCTION |
Pathogenic bacteria have developed various strategies for
acquiring iron from their hosts to support their growth, including production of siderophores to chelate iron ions from their environment and presentation of receptors to acquire iron and heme from iron- and
heme-containing proteins such as transferrin, lactoferrin, and
hemoglobin (1-3). Porphyromonas gingivalis is a highly
proteolytic Gram-negative anaerobic bacterium that is implicated as one
of the major causative pathogens for advanced adult periodontitis (4).
Heme is required for its growth (5-7). So far it has not been reported
that P. gingivalis produces siderophore (8); rather, this
bacterium elaborates a hemoglobin receptor
(HbR)1 for acquisition of
iron from hemoglobin (9, 10). HbR, a 19-kilodalton protein, was
intragenically encoded by an arginine-specific cysteine proteinase
(Arg-gingipain, RGP)-encoding gene (rgpA), a lysine-specific
cysteine proteinase (Lys-gingipain, KGP)-encoding gene
(kgp), and a hemagglutinin (HA)-encoding gene
(hagA) (11). Several pieces of evidence show that HbR forms
a large proteinase-adhesin complex with RGP, KGP, and HA proteins that
are encoded intragenically by these genes (12, 13), and appears to be
associated with a lipid A portion of lipopolysaccharide (LPS) (14).
P. gingivalis has another RGP-encoding gene
(rgpB); however, it does not encode HbR or HA (15). We found
in a previous study (11) that a purified HbR protein has the ability to
bind hemoglobin. In addition, analysis with the rgpA kgp
hagA and rgpA rgpB kgp triple mutants that failed to
express HbR on their cell surfaces revealed that HbR was indispensable for P. gingivalis cells to bind hemoglobin (16). These
findings indicate that HbR is a major component for the iron
acquisition/utilization system from hemoglobin in P. gingivalis.
Lactoferrin is an iron-binding, acute-phase protein found in saliva,
milk, and other exocrine secretions (17). Lactoferrin is secreted from
activated neutrophiles and may mediate the amplification of the
inflammatory response, phagocytosis, and regulation of myelopoiesis
(18-22). Several mechanisms for the antimicrobial action of
lactoferrin have been proposed. First, lactoferrin has the ability to
chelate iron, which results in inhibition of bacterial growth (23).
Second, it has been found that a peptide named lactoferricin, which is
liberated from lactoferrin by degradation with gastric pepsin, has a
bactericidal action. This looped peptide of the N-lobe of the
exposed surface of a lactoferrin molecule is distinct from the iron
binding region (24-26). The mechanism of bactericidal action of this
cationic peptide may be elucidated to be, as in other antimicrobial
peptides such as cecropins and magainins, that the peptide interacts
with negatively charged divalent cation binding sites on bacterial cell
surfaces such as LPS, disrupts these sites, and leads to the uptake of
peptides across the outer membrane. The affected membrane forms a
channel, resulting in leakage of cytoplasmic molecules and cell death
(27, 28). Third, it has been demonstrated recently that lactoferrin specifically inactivates colonization factors of Hemophilus
influenzae and attenuates the pathogenic potential of this
bacterium (29).
The concentration of lactoferrin rises to as high as 20 µM in the gingival crevicular fluids of patients with
localized juvenile periodontitis, gingivitis, and adult periodontitis
(30, 31). P. gingivalis cells have the ability to adsorb
lactoferrin (32), but it is not yet known what molecule(s) on the cell
surface is(are) responsible for this adsorption. In addition, it has
not been determined whether P. gingivalis cells utilize iron
from lactoferrin or whether lactoferrin attenuates their growth as an
antimicrobial agent.
In the present study, We found that human lactoferrin bound to HbR and
removed it from the cell surface of P. gingivalis and that
the lactoferricin region of lactoferrin and the N-terminal anion-rich
region of HbR might be responsible for the interaction of lactoferrin
with HbR. We also found that lactoferrin could not support the growth
of P. gingivalis as an iron source. In contrast, the growth
of P. gingivalis was inhibited by lactoferrin when it was
grown in a rich medium containing hemoglobin as the sole iron source.
 |
EXPERIMENTAL PROCEDURES |
Strains, Media, and Conditions for Cell Growth--
P.
gingivalis strains used here are listed in Table
I. P. gingivalis cells were
grown anaerobically (10% CO2, 10% H2, and 80% N2) in enriched brain heart infusion (BHI) medium and
on enriched tryptic soy agar (11). Hemin (Wako, Japan) was used
routinely as the iron source at 7.7 µM. For
hemoglobin-containing enriched BHI medium, human hemoglobin was added
to the medium at 50 nM.
Proteins and Proteinase Inhibitors--
Human hemoglobin, human
globin, human iron-saturated lactoferrin, and human milk lactoferrin
(6% iron-saturated) were purchased from Sigma. Bovine lactoferricin
(lactoferricin B) (24) was a gift from Nutritional Science Laboratory,
Morinaga Milk Industry, Zama, Japan. Proteinase inhibitors,
N -p-tosyl-L-lysine
chloromethyl ketone (TLCK), and iodoacetamide were purchased from
Sigma, and leupeptin and phenylmethylsulfonyl fluoride (PMSF) were
obtained from Peptide Institute (Minch, Japan) and Nacalai Tesque
(Kyoto, Japan), respectively.
Surface Plasmon Resonance Analysis--
HbR protein was
overproduced in Esherichia coli BL21(DE3) harboring pKD349,
which contains the HbR domain region DNA, and purified as described
previously (11). The interactions of HbR with several proteins were
determined by surface plasmon resonance analysis using a BIAcore
instrument (BIAcore 2000; Amersham Pharmacia Biotech). HbR was
cross-linked to the dextran matrix of the sensor chip (CM5; Amersham
Pharmacia Biotech). The dextran matrix was activated with
N-hydroxysuccinimide (Sigma) and N-ethyl
N'-[3-(dimethylamino)propyl]-carbodiimide hydrochloride
(Sigma). HbR (100 µg/ml) was injected at a flow rate of 5 µl/min
for 8 min in 10 mM acetate buffer (pH 3.5), and unreacted
sites in the matrix were blocked with 1 M ethanolamine hydrochloride (pH 8.5) (Sigma). The running buffers used in acidic and
neutral conditions were 50 mM acetate buffer (pH 5.5) and 50 mM Tris-HCl (pH 7.5), respectively. Several proteins in
the running buffers were passed over the chip at a rate of 10 µl/min for 4 min followed by a wash of the buffers alone for 8 min.
Their binding to HbR was measured in real time by changes in optical properties near the sensor surface. The sensor surfaces were
regenerated between assays by a 5-min injection of 50 mM
Tris-HCl buffer (pH 9.0) for removal of hemoglobin and by a 5-min
injection of 0.2 M EDTA (pH 11.0) for removal of
lactoferrin. All BIAcore analyses were carried out at 25 °C. The
estimation of the rate constants of dissociation
(kd) and association (ka)
were performed using a software package (BIAevaluation 2.1, Amersham Pharmacia Biotech) in which the data from the sensorgrams were calculated for kd using the following equation:
ln(Rt1/Rtn) = kd × t;
Rt1, the response unit (RU) of signal at
the time of the initial stage of the dissociation
(t1); Rtn, RU at time
tn; t, tn t1. ka was calculated by
the equation: (dRU/dt)/RU = ka × C + kd; dRU/dt, change of RU
by time; C, concentration of lactoferrin. The dissociation
constant (Kd) of protein-protein binding was
calculated from the following equation: Kd = kd/ka.
Dot Blot Analysis--
P. gingivalis cells grown in
enriched BHI medium for 48 h were harvested by centrifugation at
9000 × g for 5 min, washed with phosphate-buffered
saline (PBS) (pH 7.4), and resuspended in the original volume of PBS.
The washed cells (5 µl) were blotted directly onto a nitrocellulose
membrane (Bio-Rad). This membrane was then blocked with PBS containing
0.5% skim milk (Difco) and 0.2% Tween 20 for 1 h and probed for
1 h with diluted (1:1000) human milk lactoferrin that had been
conjugated with horseradish peroxidase (HRP, Sigma) according to
Kishore et al. (33). Unbound HRP-conjugated lactoferrin was
removed by washing with PBS four times for 5 min each. HRP-conjugated
lactoferrin was stained using an HRP color substrate
(4-chloro-1-napthol, Sigma). All steps were performed at room
temperature. For hemoglobin preincubation, the blotted membrane after
blocking was treated with PBS containing hemoglobin at the indicated
concentration and 0.2% Tween 20 for 1 h and washed twice with
PBS. The subsequent procedures were the same as above.
For analysis of lactoferrin-HbR interaction on a membrane, human milk
lactoferrin (5 µg) was spotted onto a nitrocellulose membrane and
left to dry. The membrane was blocked with 2% bovine serum albumin in
Tris-buffered saline (TBS)-Tween (20 mM Tris-HCl (pH 7.5),
137 mM NaCl, 0.1% Tween 20) for 1 h and washed with TBS-Tween three times for 10 min each. The membrane was then incubated in TBS-Tween containing 10% glycerol and 10 µg/ml HbR or a mutant HbR for 1 h. After being washed with TBS-Tween three times for 10 min each, the membrane was incubated in TBS-Tween containing anti-HbR
rabbit serum (1:1, 000) for 1 h, washed with TBS-Tween three
times, incubated in TBS-Tween containing the HRP-conjugated anti-rabbit
IgG (1:2, 000) (Santa Cruz Biotechnology) for 30 min, and washed
again three times with TBS-Tween. All the procedures were done at room
temperature. The peroxidase activity was detected by exposure of the
membrane to x-ray film using ECL detection systems (Amersham Pharmacia Biotech).
Treatment of P. gingivalis Cells with Lactoferrin or
Lactoferricin and Immunodetection of HbR--
P. gingivalis
cells in 48 h culture were harvested by centrifugation at
9000 × g for 5 min, washed with PBS twice, and then resuspended in 0.5 volume of PBS. Human milk lactoferrin or
lactoferricin B was added to a series of cell suspensions to final
concentrations of 0, 6.2, 13.6, and 24.8 µM. These
mixtures were kept at 37 °C for 90 min. After treatment, TLCK and
leupeptin were added at 100 µM, and the mixtures were
centrifuged at 9000 × g for 5 min to separate them
into supernatants and cell precipitates. The cell precipitates
were then resuspended in an equal volume of PBS. These supernatants and
cell suspensions were boiled after being mixed with one-sixth volume of
the sample buffer for SDS-PAGE. Samples (10 µl) were subjected to
SDS-PAGE (15% gel) and electrotransferred to a nitrocellulose
membrane. Membranes were blocked by PBS containing 5% skim milk for
1 h, washed twice with TBS-Tween, and incubated in TBS-Tween
containing anti-HbR rabbit antiserum (1:1000) or anti-fimbrillin
rabbit antiserum (1:2000) for 1 h. Membranes were washed with
TBS-Tween three times for 5 min each, incubated in TBS-Tween containing
the HRP-conjugated anti-rabbit immunoglobulin antiserum (1:2000) (Santa
Cruz) for another 1 h, and then washed with TBS-Tween another
three times. Detection of the peroxidase activity was the same as
described above.
Construction of an E. coli Strain Overexpressing a
Truncated Mutant HbR--
The nucleotide sequence encoding the amino
acid sequence of HbR from the 28th residue (Gly-28) to the last residue
(Lys-135) was amplified from pKD349 DNA by PCR with oligonucleotide
primers (upper primer, 5'-GACATATGGGTCAGGGTTGGCTCTGTC-3'; lower primer, 5'-CTGGATCCTATTTGGCGCCATTGGC-3'). The PCR product was cloned into pCR2.1 (Invitrogen), and further subcloned into pET11a at the NdeI and BamHI regions, resulting in pKD385.
E. coli BL21(DE3) harboring pKD385 produced a truncated
mutant HbR (HbR(del27)) losing the first 27 N-terminal amino
acid residues.
Purification of HbR(del27)--
For purification of HbR(del27),
E. coli BL21(DE3) harboring pKD385 was grown to an
absorbance at 540 nm of 0.5 in 300 ml of L broth containing 50 µg/ml ampicillin.
Isopropyl-l-thio- -D-galactopyranoside was added to the
culture at a concentration of 1 mM, and the culture was
incubated for another 2 h period to overproduce HbR(del27). The
cells were collected by centrifugation at 9000 × g for
5 min, resuspended in 10 ml of Tris buffer (50 mM Tris-HCl,
pH 8.0), and disrupted by sonic oscillation. After centrifugation at
9000 × g for 15 min, the precipitate was washed twice
with Tris buffer, dissolved in Tris buffer containing 6 M
guanidine-HCl, and centrifuged at 9000 × g for 10 min
to remove insoluble materials (HbR(del27) was found in an inclusion
body). The supernatant was mixed with the same volume of glycerol and
dialyzed against Tris buffer containing 75% glycerol at 4 °C
overnight. The dialyzed solution was diluted with Tris buffer to a
glycerol concentration of 10%.
Silver Staining of LPS--
LPS samples were prepared according
to the method of Perez and Blaser (34). After the samples were
subjected to SDS-PAGE (15% gel), LPS on the gel was fixed and
visualized by the method of Hitchcock (35).
 |
RESULTS |
Binding of Lactoferrin to the Intact Cell Surfaces of Various P. gingivalis Mutants--
In a previous study (16), we found that
hemoglobin could bind to the cell surfaces of P. gingivalis
ATCC 33277 (wild type), KDP129 (kgp), KDP133 (rgpA
rgpB), and KDP134 (rgpA kgp). On the other hand,
neither KDP136 (rgpA rgpB kgp) nor KDP137 (rgpA kgp hagA) had the ability to bind hemoglobin. These previous results were consistent with the presence or absence of HbR on the cell surfaces. Together with the finding that HbR has the ability to bind
hemoglobin, they indicate that HbR is the most important receptor for hemoglobin in P. gingivalis. Here, the dot blot
assay with HRP-conjugated lactoferrin showed that the intact cells of the wild type, kgp, and rgpA rgpB strains could
adsorb lactoferrin, whereas the rgpA kgp, rgpA rgpB
kgp, and rgpA kgp hagA strains could not (Fig.
1a). The lactoferrin
adsorption was very similar to hemoglobin adsorption in the strains
used except for the rgpA kgp mutant, indicating that
lactoferrin adsorption by P. gingivalis cells may be
attributable to the presence of HbR on the cell surface.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 1.
Dot blot assays. a, binding
of lactoferrin to various P. gingivalis mutant cells. Cells
were anaerobically grown in enriched BHI medium containing 7.7 µM hemin for 48 h, harvested, and resuspended in an
equal volume of PBS. After 5 µl of the cell suspension were spotted
onto a nitrocellulose membrane, the membrane was incubated with
HRP-conjugated lactoferrin. Dots: 1, ATCC 33277;
2, KDP129; 3, KDP133, 4, KDP134;
5, KDP136; 6, KDP137. b, inhibition of
adsorption of lactoferrin to P. gingivalis cell surfaces by
preincubation with hemoglobin. Cells of ATCC 33277 were spotted onto a
nitrocellulose membrane. Before treatment with HRP-conjugated
lactoferrin, the membrane was incubated with hemoglobin at various
concentrations for 1 h. Dots 1-4: 0, 5, 10, and 20 µM, respectively.
|
|
Ability of Lactoferrin to Bind HbR--
We determined the ability
of lactoferrin to bind HbR by surface plasmon resonance analysis with
an HbR-immobilized sensor chip (Table
II). The dissociation coefficients
between lactoferrin and HbR were calculated from sensorgrams using a
series of concentrations of samples. Interestingly, lactoferrin
strongly bound HbR at both pH 5.5 and 7.5, whereas hemoglobin showed
strong HbR binding only at acidic pH in this cell-free system as
previously found (11). Both iron-saturated and 6% iron-saturated
lactoferrin could bind HbR. In addition, globin was found to bind HbR,
implying that the interaction of HbR with hemoglobin may occur at
protein proportions rather than heme. Neither bovine serum
albumin nor human ferritin could bind HbR (data not shown). Free HbR
efficiently inhibited the binding between lactoferrin and the
immobilized HbR in a concentration-dependent manner (data
not shown).
Inhibition of the Binding of Hemoglobin to HbR by
Lactoferrin--
To clarify the interaction between lactoferrin and
hemoglobin in the binding to HbR, we tested the binding of
hemoglobin to the HbR-immobilized sensor chip on which lactoferrin had
been passed three times in advance. The binding of hemoglobin to HbR was completely diminished when lactoferrin was prebound to the chip at
a saturation level (Fig. 2). A similar
result was obtained in the binding of lactoferrin to a
hemoglobin-prebound HbR-immobilized chip (data not shown). To determine
whether this inhibition takes place on the surfaces of intact P. gingivalis cells, we adopted the dot blot assay. Thus, we examined
the binding of HRP-conjugated lactoferrin to intact P. gingivalis cells that had been blotted on a nitrocellulose
membrane and preincubated with various concentrations of hemoglobin
(Fig. 1b). Adsorption of lactoferrin to the cells was
inhibited by preincubation with hemoglobin in a
concentration-dependent manner. These results indicate that
lactoferrin and hemoglobin competitively bind HbR on P. gingivalis cell surfaces.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 2.
Inhibition of hemoglobin adsorption to HbR by
lactoferrin. Lactoferrin (1.27 µM) in acidic buffer
(50 mM acetate buffer, pH 5.5) was passed over the
HbR-immobilized sensor chip for 120 s, followed by a wash of the
acidic buffer alone for 120 s. After this procedure was repeated,
the lactoferrin solution was passed over the chip for 60 s,
followed by a wash of the acidic buffer alone for 240 s.
Hemoglobin (0.64 µM) in the acidic buffer was then passed
onto the chip for 150 s, followed by a flow of the acidic buffer
alone. Inset, hemoglobin (0.64 µM) in the
acidic buffer was passed on the HbR-immobilized chip for 150 s,
followed by a flow of the acidic buffer alone. Lf,
lactoferrin; Hb, hemoglobin.
|
|
Lactoferrin-mediated Growth Suppression of P. gingivalis Cells in
Hemoglobin-containing Medium--
P. gingivalis wild type
strain was able to grow in enriched BHI medium containing 50 nM hemoglobin as well as in medium containing 7.7 µM hemin (data not shown). To clarify the effect of
lactoferrin on the growth of the P. gingivalis cells, the
cells were incubated in the hemoglobin- or hemin-containing medium to
which lactoferrin was added at various concentrations. Cell growth was
significantly retarded in the hemoglobin-containing medium supplemented
with lactoferrin at 13.6 and 24.8 µM (Fig.
3a). On the other hand, lactoferrin did not suppress the growth of P. gingivalis
cells in the hemin-containing medium even at 24.8 µM
(Fig. 3b). The rgpA kgp mutant showed no
lactoferrin binding but did show hemoglobin binding (Fig.
1a, Ref. 16). Interestingly, the lactoferrin-mediated growth
suppression of the rgpA kgp mutant in the
hemoglobin-containing medium was weaker than that of the wild type
parent (Fig. 3e). These results indicate that the growth
retardation by lactoferrin may be due to the ability of lactoferrin to
access HbR, to interfere with the HbR-hemoglobin interaction, and
consequently, to disrupt the iron uptake system from hemoglobin.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 3.
Effects of lactoferrin and lactoferricin on
P. gingivalis cell growth. a, P. gingivalis (ATCC 33277) was grown in enriched BHI medium
containing hemoglobin (50 nM) and various concentrations of
lactoferrin. Closed circles, 0 µM human milk
lactoferrin; open circles, 6.2 µM; open
triangles, 13.6 µM; closed triangles,
24.8 µM. b, same as a except that
hemin (7.7 µM) was added instead of hemoglobin.
c, the same as a except that lactoferricin B was
used instead of lactoferrin. d, the same as a
except that lactoferricin B and hemin were used instead of lactoferrin
and hemoglobin, respectively. e, ATCC 33277 (open
and closed circles) and KDP134 (open and
closed triangles) were grown in enriched BHI medium
containing hemoglobin (50 nM) with lactoferrin (24.8 µM) (open symbols) or without it (closed
symbols). f, the same as e except that hemin
(7.7 µM) was added instead of hemoglobin.
|
|
To determine whether P. gingivalis cells can utilize
lactoferrin as an iron source, iron-deprived cells of the wild type
strain were incubated in enriched BHI medium containing lactoferrin or hemin as the sole iron source. No growth was observed in enriched BHI
medium containing iron-saturated lactoferrin (6.2 µM) up
to 90 h after inoculation, whereas the cells were fully grown in enriched BHI medium containing hemin, indicating that P. gingivalis cannot utilize lactoferrin as an iron source (data not shown).
Release of HbR from P. gingivalis Cell Surfaces by
Lactoferrin--
To determine whether lactoferrin affects P. gingivalis cell surfaces, we treated P. gingivalis
cells with lactoferrin at the same concentrations as those of
lactoferrin in the gingival crevicular fluids of patients with
acute inflammation (up to 24.8 µM) and healthy subjects
(about 6.2 µM) (30, 31). We separated the lactoferrin-containing cell suspension into the cell precipitates and
supernatants by centrifugation and examined the presence of LPS,
fimbrillin, and HbR in each portion. Lactoferrin did not release LPS in
the conditions used in these experiments (Fig. 4a). No change was seen in the
amounts of fimbrillin in the supernatants before and after lactoferrin
treatment (Fig. 4b). However, HbR appeared in the
supernatants after lactoferrin treatment in a concentration-dependent manner (Fig. 4c). In
contrast, no HbR was released when P. gingivalis cells were
treated with hemoglobin even at a high concentration (Fig.
4d). These results indicate that HbR is released
specifically from the cell surfaces by the lactoferrin treatment. The
lactoferrin-mediated HbR release was effectively inhibited by the
addition of iodoacetamide and a mixture of TLCK and leupeptin but not
by the addition of PMSF, implying that RGP and/or KGP proteinase domain
proteins may be involved in this HbR release (Fig. 4e). The
HA proteins, which were also encoded by rgpA, kgp, and
hagA as intragenic domain proteins, were not released from
the cell surface by lactoferrin treatment (Fig. 4f). The
lactoferrin treatment caused no change in viability of P. gingivalis (data not shown).

View larger version (61K):
[in this window]
[in a new window]
|
Fig. 4.
Silver staining and immunoblot analyses.
P. gingivalis cells ATCC 33277 were grown in enriched BHI
medium for 48 h, harvested by centrifugation, washed twice with
PBS, and then resuspended in 0.5 volume of PBS. Human milk lactoferrin
was added to a series of cell suspensions to final concentrations of 0, 6.2, 13.6, and 24.8 µM. These mixtures were kept at
37 °C for 90 min and then centrifuged at 9000 × g
for 5 min to separate them into supernatants and cell precipitates.
Cell precipitates were resuspended in an equal volume of PBS. A, silver
staining for LPS. The supernatant (500 µl) of the lactoferrin-treated
sample was mixed with 250 µl of the lytic buffer (125 mM
Tris-HCl (pH 6.8), 20% glycerol, 5% 2-mercaptoethanol, 5% SDS) and
boiled for 10 min. After cooling, 25 µl of 2.5 mg/ml proteinase K
were added to the mixture and incubated at 60 °C for 1 h,
followed by boiling for 5 min to inactivate the enzyme. After treatment
with phenol, the samples were subjected to SDS-PAGE (15% gel), and the
gel was silver-stained for LPS. Lane 1, no lactoferrin
treatment; lane 2, lactoferrin (24.8 µM)
treatment. b, immunoblot analysis of the lactoferrin-treated
samples with anti-fimbrillin antiserum. The supernatant (lanes
1-4) and the suspension of the cell precipitate (lanes
5-8) of the lactoferrin-treated sample were subjected to
SDS-PAGE. The separated proteins in the gel were transferred to a
nitrocellulose membrane. The membrane was immunostained with
anti-fimbrillin antiserum. Lactoferrin concentrations: lanes
1 and 5, 0 µM; lanes 2 and
6, 6.2 µM; lanes 3 and
7, 13.6 µM; lanes 4 and
8, 24.8 µM. c, immunoblot analysis
of the lactoferrin-treated samples with anti-HbR antiserum. The
procedure was the same as in b except that anti-HbR
antiserum was used instead of anti-fimbrillin antiserum. d,
immunoblot analysis of the hemoglobin-treated samples with anti-HbR
antiserum. The procedure was the same as c except that
hemoglobin was used instead of lactoferrin. e, lactoferricin
B-mediated HbR release and effect of proteinase inhibitors on the HbR
release. Lactoferrin (24.8 µM, lanes 2-5) or
lactoferricin B (24.8 µM, lanes 6-9) was
added to the cell suspension with iodoacetamide (10 mM,
lanes 3 and 7), PMSF (7.5 mM,
lanes 4 and 8), a mixture of TLCK (100 µM) and leupeptin (100 µM, lanes
5 and 9), or without inhibitors (lanes 2 and
6). After treatment, the cells were precipitated by
centrifugation, and the supernatants were subjected to SDS-PAGE and
immunoblot analysis with anti-HbR antiserum. Lane 1 contains
the supernatant from the cell suspension with no treatment.
f, the same as e except that anti-HA monoclonal
antibody (61BG1.3) was used instead of anti-HbR antiserum. Lane
CE contains the cell extract of the cell suspension with no
treatment.
|
|
HbR is intragenically encoded by rgpA, kgp, and
hagA. To determine from which gene(s) the HbR released by
lactoferrin is derived, we examined various mutants for
lactoferrin-mediated HbR release (Fig.
5). The rgpA rgpB double
mutant and the kgp mutant showed the lactoferrin-mediated
HbR release as well as the wild type parent, whereas the rgpA
kgp double mutant showed no HbR release. Interestingly, the
lactoferrin-mediated HbR release was suppressed by leupeptin and TLCK
in the rgpA rgpB mutant but not in the kgp mutant.

View larger version (94K):
[in this window]
[in a new window]
|
Fig. 5.
Immunoblot analyses with various
mutants. The supernatants of the lactoferrin-treated samples of
ATCC 33277 (a), KDP133 (b), KDP129
(c), and KDP134 (d) were subjected to SDS-PAGE.
The separated proteins in the gel were transferred to a nitrocellulose
membrane. The membrane was immunostained with anti-HbR antiserum.
Lanes: 1, lactoferrin, 0 µM;
2, lactoferrin, 13.6 µM; 3,
lactoferrin, 24.8 µM; 4, lactoferrin, 24.8 µM with leupeptin, 100 µM and TLCK, 100 µM; 5, lactoferrin, 24.8 µM with
PMSF, 7.5 mM. Lane 6 contains the cell extracts
of those strains with no treatment.
|
|
Growth Retardation and HbR Release by Lactoferricin
B--
Pepsin-digested lactoferrin, as well as intact lactoferrin,
caused the release of HbR from the cell surface, whereas trypsin digestion abolished the ability of lactoferrin to release HbR (data not
shown). Because these results suggested the possibility that the
effects of lactoferrin on P. gingivalis cells might be attributable to the lactoferricin region of a lactoferrin molecule, we
went on to examine whether lactoferricin caused the growth retardation
and HbR release. We used bovine lactoferricin (lactoferricin B) in this
experiment. Lactoferricin B is a 25-amino acid-long peptide including 8 cationic residues, which is located at the N-lobe of bovine
lactoferrin and generated by pepsin hydrolysis (24). Growth retardation
of the P. gingivalis wild type strain occurred when
lactoferricin B was added to the medium containing hemoglobin at the
same molar concentrations as human lactoferrin, but it did not take
place in the hemin-containing medium (Fig. 3, c and
d). Treatment of the P. gingivalis wild type
cells with lactoferricin B caused the HbR release, which was suppressed
by the addition of iodoacetamide and a mixture of TLCK and leupeptin but not by the addition of PMSF (Fig. 4e). No release of HA
proteins was observed in the lactoferricin treatment (Fig.
4f). No change was seen in the viability of P. gingivalis before and after the treatment. These results with
lactoferricin B were consistent with those of the lactoferrin
treatment, indicating that the lactoferricin region is responsible for
the effects of lactoferrin on P. gingivalis cells.
No Binding of Lactoferrin to a Truncated Mutant HbR--
The
lactoferricin region has a number of cationic amino acid residues. On
the other hand, anionic residues reside preferentially in the
N-terminal region of HbR (8 Glu and Asp residues in the first 27 residues). To determine whether the N-terminal region of HbR
contributes to the HbR-lactoferrin interaction, we constructed an
E. coli overexpressing a truncated mutant HbR (HbR(del27)) in which the first 27 amino acid residues were absent (see
"Experimental Procedures"). Dot blot analysis with the purified
HbR(del27) revealed that the truncated HbR had no ability to bind
lactoferrin, indicating that the N-terminal anion-rich region may
interact with the cationic lactoferricin region of lactoferrin (Fig.
6).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 6.
No binding of a truncated HbR with
lactoferrin. Human milk lactoferrin (dot 1), wild-type
HbR (dot 2), and HbR(del27) (dot 3) (5 µg each)
were spotted onto a nitrocellulose membrane. The membrane was blocked
with bovine serum albumin and incubated with wild-type HbR
(panel a) or HbR(del27) (panel b). HbR on
the membrane was detected using anti-HbR rabbit antiserum and
HRP-conjugated anti-rabbit IgG antiserum.
|
|
Effect of Haptoglobin on the Binding of Hemoglobin to
HbR--
Haptoglobin has the ability to bind hemoglobin (36) and
suppress the growth of P. gingivalis in a medium containing
hemoglobin (37). To determine whether this growth suppression by
haptoglobin is involved in the interaction of hemoglobin with HbR, the
effect of haptoglobin on the binding of hemoglobin to HbR was examined. Haptoglobin inhibited the binding of hemoglobin to HbR as revealed by
surface plasmon resonance analysis (Fig.
7).

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 7.
Effect of haptoglobin on the interaction of
hemoglobin with HbR. The neutral running buffer containing
hemoglobin (0.32 µM) and/or haptoglobin (0.32 µM) was passed onto the HbR-immobilized sensor chip.
Hb, hemoglobin; Hp, haptoglobin.
|
|
 |
DISCUSSION |
Although P. gingivalis grows well in a medium
containing hemin or hemoglobin as an iron source, the concentration of
hemoglobin required to support its growth is much lower than that of
hemin. The concentrations of hemin and hemoglobin to support
50% of the maximal growth rates are 1-5 µM and 1.7 nM, respectively (37), which implies that the iron
uptake/utilization systems from hemin and hemoglobin may have, at least
in part, different pathways. In a previous study (11), we presented a
hypothetical mechanism of the iron uptake/utilization from
erythrocytes. We showed that P. gingivalis cells may adhere
to erythrocytes by the HA domain proteins intragenically encoded by
rgpA, kgp and hagA. After this adherence,
the RGP and/or KGP proteinases may extensively digest surface proteins
of erythrocytes, resulting in the release of hemoglobin. Released
hemoglobin may then be captured by the HbR proteins and proteolytically
degraded to release heme. The heme may then be stored on the surfaces
of P. gingivalis cells and utilized by the bacterium. By
genetic analysis, HbR was found to be the major hemoglobin receptor
protein in P. gingivalis (16). We found that haptoglobin, a
natural hemoglobin-binding protein, had the ability to inhibit the
interaction of hemoglobin with HbR by forming a haptoglobin-hemoglobin
complex, revealed by surface plasmon resonance analysis with an
HbR-immobilized chip. It was reported that haptoglobin suppresses the
growth of P. gingivalis in a medium containing hemoglobin
(37). These results strongly suggest that HbR may play a crucial role
in the acquisition of iron from hemoglobin in a natural niche for
P. gingivalis.
In this study, we found that lactoferrin, as well as hemoglobin, bound
HbR. Lactoferrin is thought to play a pivotal role in the prevention of
infection in the host and its ability to sequester iron from potential
pathogens has been regarded as an antimicrobial function (23). The
antimicrobial function of lactoferrin may not simply be because of the
removal of free iron ions from the environment but may involve the
interaction between lactoferrin and cell surfaces of microorganisms
(38). Moreover, lactoferrin effectively bound to the cell surface of
P. gingivalis. The results with the various mutants used,
except the rgpA kgp mutant, suggest that lactoferrin binding
to the cell surface is attributable to the presence of HbR. The
rgpA kgp mutant has HbR on the cell surface. However, the
reactivity of the mutant cells to anti-HbR antiserum is significantly
weaker than that of the wild type (16). No lactoferrin binding of the
rgpA kgp mutant may be explained by the possibility that the
circumstances around HbR on the cell surface of the mutant are
different from those of HbR derived from the rgpA and
kgp genes, and this difference changes the accessibility of
lactoferrin to HbR because all HbR in the mutant should come from the
hagA gene. HbR shares no similarities with the known lactoferrin-binding proteins of prokaryotes such as LbpA and LbpB of
Neisseria meningitidis (39).
We also found that lactoferrin suppressed the growth of P. gingivalis in the medium containing hemoglobin as the sole iron source but not in the medium containing hemin. In several Gram-negative bacteria, lactoferrin damages their outer membranes and releases LPS
from the cells (40). In P. gingivalis, no significant
release of LPS, fimbriae/fimbrillin, or the HA proteins was found after lactoferrin treatment. In addition, the treatment produced no change in
the viability of P. gingivalis. In contrast, lactoferrin removed HbR from P. gingivalis cells. Recently, Qiu et
al. (29) found that human milk lactoferrin efficiently extracted
IgA1 proteinase preprotein from the cell surface of H. influenzae and degraded Hap adhesin and that PMSF completely
suppressed the IgA1 extraction and the Hap degradation. IgA1 proteinase
and Hap are produced as large polyproteins comprising four and three
domains, respectively (41-43). Because the rgpA and
kgp gene products were polyproteins consisting of the
proteolytic domain proteins (RGP and KGP), HbR, and HA, we investigated
whether the potential proteolytic activity of lactoferrin was involved
in the release of HbR from the cell surface. The results showed that
PMSF did not affect the lactoferrin-mediated HbR release, but
interestingly, iodoacetamide and a mixture of leupeptin and TLCK that
had the potential to inhibit RGP and KGP proteinases did inhibit the
HbR release. HbR makes a complex with proteinase domains and HA
domains, and these domains are covalently bound to one another in the
early period of growth phase (44). After this period, these domains are
separated by RGP and KGP proteinases although the domain proteins
remain non-covalently associated (12, 44, 45). Therefore, the
inhibitory effect of the proteinase inhibitors on the
lactoferrin-mediated HbR release may be due to the inactivation of RGP
and KGP proteinase activity that results in inhibition of processing of
the polyproteins. However, this explanation seems unlikely
because the HbR released into the supernatant appeared to be directly
derived from the 19-kDa HbR already processed from the polyprotein, as
judged by the finding that the cell-bound HbR before lactoferrin
treatment also migrated at a molecular mass of 19 kDa on SDS-PAGE;
after treatment the cell-bound 19-kDa HbR decreased in a
concentration-dependent fashion. What interaction between
lactoferrin and HbR causes the HbR release? We found that lactoferrin
did not bind the truncated HbR in which the first 27 amino acid
residues, including 8 anionic residues, were deleted and that the
growth retardation and HbR release occurred by treatment of
lactoferricin B as well as lactoferrin. These results suggest that the
cationic lactoferricin region of lactoferrin may interact with the
N-terminal anion-rich region of HbR in an electrostatic action, loosen
the non-covalent bond between HbR and other components of the complex,
and release HbR from the cell surface (Fig.
8). The inhibitory effect of the
proteinase inhibitors on the HbR release suggests that a conformational
change of the proteinase domain proteins, which can be hindered by the inhibitors, is required in the process of HbR release, although we
should reserve the possibility that lactoferrin directly interacts with
the proteolytic domain proteins or other components of the complex in
addition to HbR. In this context, it is noteworthy that proteinase
inhibitors such as TLCK and leupeptin suppress hemagglutination of
P. gingivalis cells, which appears to be attributable to the
HA proteins of the complex (46-48).
Growth retardation of P. gingivalis by lactoferrin depended
on the concentration of lactoferrin. However, after prolonged incubation, P. gingivalis cells grew up to a maximal level
even in the medium supplemented with large amounts of lactoferrin, probably because lactoferrin was gradually degraded by proteinases secreted from P. gingivalis and lost its bacteriostatic
action. The lactoferrin-mediated growth suppression was not observed in the medium containing hemin instead of hemoglobin. Therefore, the
retardation in growth of P. gingivalis may be a consequence of the specific interaction of lactoferrin with HbR, which is the major
hemoglobin receptor of the bacterium. These results suggest that
lactoferrin may attenuate the infection of P. gingivalis by
selectively removing HbR from the cell surface and disrupting the iron
acquisition system essential for the in vivo survival of the
bacterium and that secreted and cell-bound RGP and KGP proteinases may
function as "interceptor missiles" against lactoferrin attack.
 |
ACKNOWLEDGEMENTS |
We thank Drs. F. Yoshimura and R. Gmür
for the kind gifts of anti-fimbrillin antiserum and monoclonal antibody
61BG1.3, respectively. General assistance by K. Sakai is acknowledged
with appreciation.
 |
FOOTNOTES |
*
This work was supported by a grant-in-aid for scientific
research from the Ministry of Education, Science, Sports and Culture of
Japan.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.: +81-92-642-6332;
Fax: +81-92-642-6333; E-mail: knak@dent.kyushu-u.ac.jp.
Published, JBC Papers in Press, May 12, 2000, DOI 10.1074/jbc.M001518200
 |
ABBREVIATIONS |
The abbreviations used are:
HbR, hemoglobin
receptor;
RGP, Arg-gingipain;
KGP, Lys-gingipain;
LPS, lipopolysaccharide;
BHI, brain heart infusion;
TLCK, N -p-tosyl-L-lysine
chloromethyl ketone;
PMSF, phenylmethylsulfonyl fluoride;
HRP, horseradish peroxidase;
PBS, phosphate-buffered saline;
TBS, Tris-buffered saline;
HA, hemagglutinin;
RU, response unit;
PAGE, polyacrylamide gel electrophoresis.
 |
REFERENCES |
| 1.
|
Bagg, A.,
and Neilands, J. B.
(1987)
Microbiol. Rev.
51,
509-518
|
| 2.
|
Guerinot, M. L.
(1994)
Annu. Rev. Microbiol.
48,
743-772
|
| 3.
|
Schryvers, A. B.,
and Stojiljkovic, I.
(1999)
Mol. Microbiol.
32,
1117-1123
|
| 4.
|
Haffajee, A. D.,
and Socransky, S. S.
(1994)
Periodontol. 2000
5,
78-111
|
| 5.
|
Gibbons, R. J.,
and MacDonald, J. B.
(1960)
J. Bacteriol.
80,
164-170
|
| 6.
|
Shah, H. N.,
Bonnett, R.,
Mateen, B.,
and Williams, R. A. D.
(1979)
Biochem. J.
180,
45-50
|
| 7.
|
Smalley, J. W.,
Silver, J.,
Marsh, P. D.,
and Birss, A. J.
(1998)
Biochem. J.
331,
681-685
|
| 8.
|
Bramanti, T. E.,
and Holt, S. C.
(1990)
Biochem. Biophys. Res. Commun.
166,
1146-1154
|
| 9.
|
Fujimura, S.,
Shibata, Y.,
Hirai, K.,
and Nakamura, T.
(1995)
FEMS Immunol. Med. Microbiol.
10,
109-114
|
| 10.
|
Fujimura, S.,
Shibata, Y.,
Hirai, K.,
and Nakamura, T.
(1996)
Infect. Immun.
64,
2339-2342
|
| 11.
|
Nakayama, K.,
Ratnayake, D. B.,
Tsukuba, T.,
Kadowaki, T.,
Yamamoto, K.,
and Fujimura, S.
(1998)
Mol. Microbiol.
27,
51-61
|
| 12.
|
Pavloff, N.,
Potempa, J.,
Pike, R. N.,
Prochazka, V.,
Kiefer, M. C.,
Travis, J.,
and Barr, P. J.
(1995)
J. Biol. Chem.
270,
1007-1010
|
| 13.
|
Slakeski, N.,
Bhogal, P. S.,
O'Brien-Simpson, N. M.,
and Reynolds, E. C.
(1998)
Microbiol.
144,
1583-1592
|
| 14.
|
Sharp, L.,
Poole, S.,
Reddi, K.,
Fletcher, J.,
Nair, S.,
Wilson, M.,
Curtis, M.,
Henderson, B.,
and Tabona, P.
(1998)
Microbiology
144,
3019-3026
|
| 15.
|
Nakayama, K.
(1997)
Microbiol. Immunol.
41,
185-196
|
| 16.
|
Shi, Y.,
Ratnayake, D. B.,
Okamoto, K.,
Abe, N.,
Yamamoto, K.,
and Nakayama, K.
(1999)
J. Biol. Chem.
274,
17955-17960
|
| 17.
|
Masson, P. L.,
Heremans, J. F.,
and Dive, C.
(1966)
Clin. Chim. Acta
13,
735-739
|
| 18.
|
van Snick, J. L.,
Masson, P. L.,
and Heremans, J. F.
(1974)
J. Exp. Med.
140,
1068-1084
|
| 19.
|
Oseas, R.,
Yang, H. H.,
Baehner, R. L.,
and Boxer, L. A.
(1981)
Blood
57,
939-945
|
| 20.
|
de Vet, B. J. C. M.,
and ten Hooper, C. H.
(1978)
Acta Med. Scand.
203,
197-203
|
| 21.
|
Ambruso, D. R.,
and Johnston, R. B., Jr.
(1981)
J. Clin. Invest.
67,
352-360
|
| 22.
|
Broxmeyer, H. E.,
Smithyman, A.,
Eger, R. R.,
Meyers, P. A.,
and Desousa, M.
(1978)
J. Exp. Med.
148,
1052-1067
|
| 23.
|
Reiter, B.
(1983)
Int. J. Tissue React.
5,
87-96
|
| 24.
|
Bellamy, W.,
Takase, M.,
Yamauchi, K.,
Wakabayashi, H.,
Kawase, K.,
and Tomita, M.
(1992)
Biochim. Biophys. Acta
1121,
130-136
|
| 25.
|
Yamauchi, K.,
Tomita, M.,
Giehl, T. J.,
and Ellison, R. T., III
(1993)
Infect. Immun.
61,
719-728
|
| 26.
|
Odell, E. W.,
Sarra, R.,
Foxworthy, M.,
Chapple, D. S.,
and Evans, R. W.
(1996)
FEBS Lett.
382,
175-178
|
| 27.
|
Marion, D.,
Zasloff, D. M.,
and Bax, A.
(1988)
FEBS Lett.
227,
21-26
|
| 28.
|
Varra, M.,
and Varra, T.
(1994)
Antimicrob. Agent Chemother.
38,
2498-2501
|
| 29.
|
Qiu, J.,
Hendrixson, D. R.,
Baker, E. N.,
Murphy, T. F.,
St. Geme, J. W., III.,
and Plaut, A. G.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
12641-12646
|
| 30.
|
Friedman, S. A.,
Mandel, I. D.,
and Herrera, M. S.
(1983)
J. Periodontol.
54,
347-350
|
| 31.
|
Adonogianaki, E.,
Moughal, N. A.,
and Kiane, D. F.
(1993)
J. Clin. Periodontol.
20,
26-31
|
| 32.
|
Kalfas, S.,
Andersson, M.,
Edwardsson, S.,
Forsgren, A.,
and Naidu, A. S.
(1991)
Oral Microbiol. Immunol.
6,
350-355
|
| 33.
|
Kishore, A. R.,
Erdei, J.,
Kalfas, D.,
Forsgren, A.,
and Naidu, A. S.
(1992)
J. Med. Microbiol.
37,
341-345
|
| 34.
|
Perez, G. I. P.,
and Blaser, M. J.
(1985)
Infect. Immun.
47,
353-359
|
| 35.
|
Hitchcock, P. J.
(1983)
Eur. J. Biochem.
133,
685-688
|
| 36.
|
Eaton, J. W.,
Brandt, P.,
and Mahoney, J. R.
(1982)
Science
215,
691-692
|
| 37.
|
Shizukuishi, S.,
Tazaki, K.,
Inoshita, E.,
Kataoka, K.,
Hanioka, T.,
and Amano, A.
(1995)
FEMS Microbiol. Lett.
131,
313-317
|
| 38.
|
Valenti, P.,
Antonini, G.,
Fanelli, R.,
Orsi, N.,
and Antonini, E.
(1982)
Antimicrob. Agents Chemother.
21,
840-841
|
| 39.
|
Schryvers, A. B.,
Bonnah, R., Yu, R.,
Wong, H.,
and Retzer, M.
(1998)
Adv. Exp. Med. Biol.
443,
123-133
|
| 40.
|
Reiter, B.,
and Perraudin, J. P.
(1998)
Adv. Exp. Med. Biol.
443,
175-188
|
| 41.
|
Poulsen, K.,
Brandt, J.,
Hjorth, J. P.,
Thogersen, H. C.,
and Kilian, M.
(1989)
Infect. Immun.
57,
3097-3105
|
| 42.
|
Pohlner, J.,
Halter, R.,
Beyreuther, K.,
and Meyer, T. F.
(1987)
Nature
325,
458-462
|
| 43.
|
Hendrixson, D. R.,
de la Morena, M. L.,
Stathopoulos, C.,
and St. Geme, J. W., III
(1997)
Mol. Microbiol.
26,
505-518
|
| 44.
|
DeCarlo, A. A.,
and Harber, G. J.
(1997)
Oral Microbiol. Immunol.
12,
47-56
|
| 45.
|
Bhogal, P. S.,
Slakeski, N.,
and Reynolds, E. C.
(1997)
Microbiol.
143,
2485-2495
|
| 46.
|
Nishikata, M.,
Yoshimura, F.,
and Nodasaka, Y.
(1989)
Microbiol. Immunol.
33,
75-80
|
| 47.
|
Curtis, M. A.,
Ramakrishnan, M.,
and Slaney, J. M.
(1993)
J. Gen. Microbiol.
139,
949-955
|
| 48.
|
Pike, R. N.,
Potempa, J.,
McGraw, W.,
Coetzer, T. H. T.,
and Travis, J.
(1996)
J. Bacteriol.
178,
2876-2882
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
H. Wakabayashi, K. Yamauchi, T. Kobayashi, T. Yaeshima, K. Iwatsuki, and H. Yoshie
Inhibitory Effects of Lactoferrin on Growth and Biofilm Formation of Porphyromonas gingivalis and Prevotella intermedia
Antimicrob. Agents Chemother.,
August 1, 2009;
53(8):
3308 - 3316.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. R. Clarke and S. J. Foster
IsdA Protects Staphylococcus aureus against the Bactericidal Protease Activity of Apolactoferrin
Infect. Immun.,
April 1, 2008;
76(4):
1518 - 1526.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Paramaesvaran, K.-A. Nguyen, E. Caldon, J. A. McDonald, S. Najdi, G. Gonzaga, D. B. Langley, A. DeCarlo, M. J. Crossley, N. Hunter, et al.
Porphyrin-Mediated Cell Surface Heme Capture from Hemoglobin by Porphyromonas gingivalis
J. Bacteriol.,
April 15, 2003;
185(8):
2528 - 2537.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Shoji, D. B. Ratnayake, Y. Shi, T. Kadowaki, K. Yamamoto, F. Yoshimura, A. Akamine, M. A. Curtis, and K. Nakayama
Construction and characterization of a nonpigmented mutant of Porphyromonas gingivalis: cell surface polysaccharide as an anchorage for gingipains
Microbiology,
April 1, 2002;
148(4):
1183 - 1191.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|